Alcobra Ltd. (NASDAQ:ADHD) Lists on NASDAQ - Video Summary Posted on InvestmentPitch.com
(Thomson Reuters ONE) -
Vancouver, British Columbia, May 31, 2013 - Alcobra Ltd. is the latest new
listing on NASDAQ, and will trade under the symbol ADHD. The company completed
an IPO offering of 3,125,000 shares at US$8.00, raising US$25 million in gross
proceeds. The company now has 11,130,000 shares outstanding.
Aegis Capital Corp. acted as sole book-running manager, with Sunrise Securities
Corp. and Feltl & Company as co-managers.
InvestmentPitch. com has produced a "video news alert" describing Alcobra Ltd.
If this link is not enabled, please visit www.InvestmentPitch.com and enter
"Alcobra" in the search box.
Tel Aviv, Israel-based Alcobra, is an emerging biopharmaceutical company
primarily focused on the development and commercialization of a proprietary
drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder or ADHD. ADHD is
one of the most common behavioral disorders in the world, and it is estimated
that between 5% and 12% of children worldwide are affected by this condition.
Once believed to only affect children, ADHD is now known to persist into
adolescence and adulthood in a large number of cases, with approximately 46% of
all adults who had ADHD is children continuing to have symptoms of the disorder
as adults. ADHD is currently treated with therapeutic, stimulant drugs such as
Ritalin, which have numerous side effects, such as uncomfortable mental states,
interference with sleep and appetite, development of nervous ticks and potential
cardiovascular effects resulting from increased blood pressure..
In September 2011, Alcobra completed a 120-patient double-blind Phase II study
that demonstrated that the company's MG01CI drug provided a well-tolerated,
immediate and effective treatment.
The company's objective is to develop and commercialize proprietary
pharmaceutical products for treatment of central nervous system disorders, and
cognitive dysfunctions in particular. The company plans to conduct additional
clinical trials, and if those trials are successful, seek marketing approval
from the U.S. Food and Drug Administration, or FDA, and other worldwide
regulatory bodies for the treatment of ADHD in adults and children. Alcobra also
intends to develop additional products they have invented or that they may
acquire.
For more information about Alcobra, please visit the company's website
www.alcobra-pharma.com.
In the U.S., investor relations is handled by KCSA Strategic Communications.
Please contact Jeffrey Goldberger at 212-896-1249 or email jgoldberger(at)kcsa.com.
InvestmentPitch.com, a multimedia company that provides a combined solution for
creating and hosting financial video content, and distributing it across
multiple platforms to investors and financial professionals, specializes in
producing short three minute videos based on significant news releases and
research reports.
CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan(at)investmentpitch.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: InvestmentPitch via Thomson Reuters ONE
[HUG#1706483]
Unternehmensinformation / Kurzprofil:
Datum: 31.05.2013 - 22:43 Uhr
Sprache: Deutsch
News-ID 265407
Anzahl Zeichen: 3811
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 198 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Alcobra Ltd. (NASDAQ:ADHD) Lists on NASDAQ - Video Summary Posted on InvestmentPitch.com"
steht unter der journalistisch-redaktionellen Verantwortung von
InvestmentPitch (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
